PRME250516C1000
- 0.00
- 0.000.00%
Prime Medicine Newsroom
Prime Medicine Is Maintained at Buy by Chardan Capital
JMP Securities Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Prime Medicine Analyst Ratings
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $14
Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating
Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating
Prime Medicine Price Target Maintained With a $10.00/Share by Citizens Capital Markets
JMP Securities Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Prime Medicine Analyst Ratings
J.P. Morgan Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)
Prime Medicine, Inc.: Promising Gene Editing Developments and Strong Financial Position Justify Buy Rating
TD Cowen Maintains Prime Medicine(PRME.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)
BMO Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $19
Prime Medicine's Promising Prospects and Potential Catalysts Justify Buy Rating
JMP Securities Initiates Prime Medicine at Market Outperform With $10 Price Target
JMP Securities Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $10